I recently learned that Alan Osmond, who has Multiple Sclerosis, has experienced success with the drug called SF-1019 for his MS symptoms. His story is here: http://osmondms.com/. He has experienced “miraculous” improvements thanks to SF-1019. He went to England for initial treatments, and now gets it from a doctor in Utah.
Being the skeptic that I am, I went surfing. Results show that not everyone who has tried this drug has had the same degree of success. So although this appears to be a compound worth watching, it is not producing consistent results, yet. I’m a bit skeptical because there are a few “anecdotal” reports that this drug fixes everything that is wrong with you, including osteoporosis and bad breath (just kidding about the bad breath). But the testing group was very small (12 patients) who had a variety of maladies so more research is needed.
So what is SF-1019? It appears to be some type of anti-inflammatory medicine. It is administered via subcutaneous injection. It evolved from research into Biological Response Modifiers (BRMs), which are substances that stimulate the body's response to infection and disease, like interferons. Sound familiar?
From Immunosyn’s web site http://www.immunosyn.com/prod_sf-1019.html :
Immunosyn has been granted by Argyll Biotechnologies, LLC an exclusive, worldwide license to market, sell and distribute the product currently referred to as SF-1019 along with any possible future variants of SF-1019.
Research suggests the current product has additional developmental potential as it also possesses analgesic properties with an ability to substantially reduce the inflammation attending a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders.
Applications are currently underway with the Food and Drug Administration (FDA) for clinical trial approval of SF-1019 relating to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS). In Europe, similar applications are also being prepared for the European Medicines Agency (EMEA) for further trials relating to diabetic ulcers and other wound healing.
The MS Society UK has a very credible page that explains quite succinctly: http://www.mssociety.org.uk/research/in_the_spotlight/sf1019.html
So keep this one in the “watch for more information from credible sources” pile, and be prepared for well-meaning friends to tell you about the "latest cure" for MS.